4.5 Review

Histone deacetylase inhibitors and transplantation

Journal

CURRENT OPINION IN IMMUNOLOGY
Volume 19, Issue 5, Pages 589-595

Publisher

CURRENT BIOLOGY LTD
DOI: 10.1016/j.coi.2007.07.015

Keywords

-

Categories

Funding

  1. NIAID NIH HHS [R01 AI073938, P01 AI073489-01A10003, P01 AI073489, R01 AI073938-01A1] Funding Source: Medline

Ask authors/readers for more resources

Simply detecting the presence or absence of Foxp3, a transcription factor characteristic of naturally occurring CD4+ CD25+ regulatory T cells (Tregs), now appears of minimal value in predicting the outcome of immunologic responses, since dividing human CD4+ effectorT cells can induce Foxp3 without attaining repressive functions, and additional molecular interactions, as well epigenetic events, affect Foxp3dependent Treg functions in humans and mice. Experimentally, in vivo and in vitro studies show histone deacetylase inhibitors (HDACi) can enhance the numbers and suppressive function of regulatory T cells (Tregs) by promoting Foxp3+ cell production, enhancing chromatin remodeling within Tregs, and inducing acetylation of Foxp3 protein itself. Human studies consistent with a role for HDACi in controlling Fox3-dependent Treg functions are also available. We review these molecular interactions and how they may be exploited therapeutically to enhance Treg-dependent functions, including post-transplantation.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available